Related Experiment Video
Updated: May 6, 2026
10:28
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
7.7K
Dual antiplatelet therapy -- management in general practice
Rohan Jayasinghe1, Ryan Markham, Geoffrey Adsett
1MBBS(Hons), MSpM, PhD, FRACP, FCSANZ, MBA, is Professor of Cardiology, Griffith University and Director of Cardiac Services/Cardiology, Gold Coast Health, Queensland.
Australian Family Physician
|October 17, 2013
Summary
New antiplatelet agents like prasugrel and ticagrelor offer reduced morbidity and mortality for acute coronary syndromes. General practitioners must consider patient factors such as bleeding risk before prescribing these crucial medications.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute coronary syndromes (ACS) management increasingly involves novel antiplatelet agents.
- Growing use necessitates enhanced understanding among general practitioners (GPs).
Observation:
- Review of pharmacokinetic and pharmacodynamic properties of antiplatelet medications.
- Evaluation of clinical trial evidence supporting their therapeutic applications.
- Discussion of safety and adverse effect profiles.
Findings:
- Aspirin remains a cornerstone therapy for ACS.
- Addition of clopidogrel, prasugrel, or ticagrelor significantly reduces morbidity and mortality in select ACS patients.
- Individualized patient assessment is critical for optimal antiplatelet therapy selection.
Implications:
- GPs require updated knowledge on evidence-based antiplatelet prescribing for ACS.
- Careful consideration of patient-specific factors (bleeding risk, renal function, stent status) is essential.
- Personalized antiplatelet strategies improve ACS patient outcomes and safety.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
01:27Coronary Artery Disease V: Interprofessional Care
452
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
452
01:27Peripheral Artery Disease III: Interprofessional Care
659
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
659
01:26Angina IV: Management
496
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
496
01:29Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
01:26Atherosclerosis III: Management
747
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747